FDA Grants AP Status for Irbesartan ANDA206194 by Hisun Pharm
The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for Irbesartan submitted by Hisun Pharm.
Asset
Irbesartan
Indication
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The FDA's approval of Hisun Pharm's ANDA for Irbesartan is significant as it introduces a new competitor in the antihypertensive market, potentially impacting pricing and market dynamics. Portfolio teams must evaluate the implications for existing products and strategize accordingly to maintain market share.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the launch timeline and market entry strategies of Hisun Pharm for Irbesartan.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.